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Abstract
Alzheimer's disease (AD) is the leading cause of dementia worldwide. Mitochondrial abnormalities have been
identified in many cell types in AD, with deficits preceding the development of the classical pathological
aggregations. Ursodeoxycholic acid (UDCA), a treatment for primary biliary cirrhosis, improves mitochondrial
function in fibroblasts derived from Parkinson's disease patients as well as several animal models of AD and
Parkinson's disease. In this paper, we investigated both mitochondrial function and morphology in fibroblasts
from patients with both sporadic and familial AD. We show that both sporadic AD (sAD) and PSEN1 fibroblasts
share the same impairment of mitochondrial membrane potential and alterations in mitochondrial morphology.
Mitochondrial respiration, however, was decreased in sAD fibroblasts and increased in PSEN1 fibroblasts.
Morphological changes seen in AD fibroblasts include reduced mitochondrial number and increased
mitochondrial clustering around the cell nucleus as well as an increased number of long mitochondria. We
show here for the first time in AD patient tissue that treatment with UDCA increases mitochondrial membrane
potential and respiration as well as reducing the amount of long mitochondria in AD fibroblasts. In addition, we
show reductions in dynamin-related protein 1 (Drp1) level, particularly the amount localized to mitochondria in
both sAD and familial patient fibroblasts. Drp1 protein amount and localization were increased after UDCA
treatment. The restorative effects of UDCA are abolished when Drp1 is knocked down. This paper highlights
the potential use of UDCA as a treatment for neurodegenerative disease.
© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Alzheimer's disease (AD) is the leading cause of
dementia worldwide and is characterized by the
build-up of amyloid plaques and neurofibrillary
tangles with a loss of neurons later in the disease
course [1]. Mounting evidence indicates that amyloid
plaques and neurofibrillary tangles do not correlate
well with disease severity [2].
Mitochondrial dysfunction is a well-established
mechanism in familial and sporadic forms of AD
(sAD), with evidence from both post-mortem and
peripheral patient tissue as well as animal models.
Fluorodeoxyglucose positron emission tomography
imaging in living patients has identified hypometa-
bolism in parietal and temporal brain regions, even in
early disease. Alterations in glucose metabolism and
cellular respiration have also been found in AD
patient fibroblasts [3–7]. Post-mortem data from AD
patients show reduced activity of tricarboxylic acid
enzymes and reduced complex IV activity, with
complex IV activity decreasing during disease
progression [8,9]. Mitochondrial enzymatic failure,
reduced glucose metabolism and increased reactive
oxygen species production have all been shown to
occur before amyloid pathology [10]. Expression of
mitochondrial subunits from all respiratory chain
complexes is reduced in the entorhinal cortex (which
is an area of early pathological change in AD) of AD
patients at post-mortem [11]. In addition, similar
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changes in expression of mitochondrial genes have
been shown early in disease progression in whole
blood samples of AD patients [12]. It is not only
mitochondrial function that is altered inAD; of particular
importance in neurons is mitochondrial dynamics.
Mitochondria are in a constant state of flux undergoing
fission and fusion events allowing them to adapt and
meet local energy requirements. Evidence from both
neurons and patient fibroblasts shows that mitochon-
dria are more elongated and have altered distribution
throughout the cell [6]. In particular mitochondria
are localized around the perinuclear region in sAD
fibroblasts suggesting a collapse of the mitochondrial
network [13]. Mitochondrial dysfunction is a shared
mechanism between sAD and familial forms of AD.
Transgenic models of familial AD that incorporate
amyloid precursor protein (APP) show impaired
mitochondrial function and changes in mitochondrial
morphology, specifically reduced mitochondrial
membrane potential and tricarboxylic acid enzyme
enzymes as well as reduced ATP levels [14,15]. In
addition, genetic risk factors for AD alter mitochondrial
function. Possession of the APOE4 allele is the largest
genetic risk factor for sAD, and possession of this allele
is associated with reduced expression of respiratory
chain complex proteins and activity of complex IV
[16,17]. Much work has been done trying to elucidate
themechanismswhich causeADwith a view to finding
therapeutic targets to slow or stop the progression of
AD. To date, however, these interventions have not
succeeded in modifying clinical outcome. The search
for therapeutic targets has focused mostly around the
amyloid cascade.
Mitochondrial abnormalities are also found in fibro-
blasts of patients with other neurodegenerative dis-
eases. We and others have extensively characterized
these changes in Parkinson's disease (PD) genetic
subtypes [18–23] and MND sporadic and genetic
subtypes [24,25]. We were the first to use the
mitochondrial functional deficits as a primary screen
in a drug screening cascade for PD [20]. We identified
ursodeoxycholic acid (UDCA) in a drug screen of
fibroblasts from parkin mutant PD patients, which we
have subsequently validated in other forms of PD
and other model systems [21]. UDCA is a promising
compound as it is already in clinical use for the
treatment of primary biliary cirrhosis.
We therefore hypothesized that mitochondrial
abnormalities are detectable in fibroblasts from
sAD and familial presenilin 1 (PSEN1) patients,
and that these abnormalities could be improved with
UDCA treatment. Here we describe our findings of
mitochondrial membrane potential, mitochondrial
morphology and localization, metabolic activity and
Q2
Fig. 1. (A) Mitochondrial membrane potential in each of the seven sporadic and three familial AD lines. When compared
to controls (n = 7), all sporadic lines and all familial lines showed a significant reduction in mitochondrial membrane
potential (*p b 0.05, **p b 0.01, ***p b 0.005). (B) The total mitochondrial count was significantly reduced in both sporadic
(*p b 0.05) and familial groups (*p b 0.05). (C) Perinuclear mitochondrial count was significantly increased in both sporadic
(*p b 0.05) and familial (***p b 0.005) groups. (D) The percentage of cell area occupied by longmitochondria is increased in both
sAD and PSEN1 patient fibroblasts (*p b 0.05). (E) Correlation of mitochondrial membrane potential and % long mitochondria
shows negative correlation (p = 0.0002, R2 = 0.7). The circles represent controls; triangles, sAD; and squares, PSEN1. All
measurements were carried out on three separate passages of each fibroblast line.
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mitochondrial fission/fusion machinery expression in
sAD and PSEN1 fibroblasts. In addition, we describe
a new mode of action of UDCA on mitochondrial
respiration which is abolished when dynamin-related
protein 1 (Drp1) is knocked down, indicating that
Drp1 is involved in the recovery mechanism in AD.
Results
Mitochondrial function andmorphology are altered
in both sAD and PSEN1 patient fibroblasts
We initially investigated global mitochondrial func-
tion and morphology to address if there is a general
mitochondrial phenotype present in AD.We assessed
these mitochondrial parameters in two separate
cohorts of fibroblasts from sAD patients, one collected
locally (Sheffield cohort, n = 4) and one sourced from
the Coriell cell repository (n = 3) in addition to a cohort
of PSEN1 patient lines (n = 3 also sourced from
Coriell cell repository and compared to controls (n = 4
from Sheffield and n = 3 from Coriell). We found
reduced mitochondrial membrane potential in all sAD
fibroblasts (controls 100 ± 5.3, sAD 83 ± 9; p b 0.05)
and PSEN1 fibroblasts (controls 100 ± 5.3, PSEN1
71 ± 1.1; p b 0.01; Fig. 1A). Every AD fibroblast line
had a significant reduction inmitochondrialmembrane
potential, ranging from a 35% to an 8% reduction.
In these same lines (both sAD cohorts and the
PSEN1 fibroblasts), we also identified significant
alterations in mitochondrial morphology and subcel-
lular localization (Fig. 1B and C). We analyzed
the mitochondria as three different entities: long
mitochondria defined as mitochondria with form
factor N 0.48, short mitochondria defined as mito-
chondria with form factor b0.48 and all mitochondria.
When considering total mitochondria, mitochondrial
count per cell was reduced in the sporadic group
(controls 100 ± 11.3, sAD 82.3 ± 11.5; p b 0.05;
Fig. 1B) and in the PSEN1 group (controls 100 ± 11.3,
PSEN 55.8 ± 18.3; p b 0.05; Fig. 1B). In both
the sporadic and PSEN1 groups, the localization of
mitochondria was focused more around the cell
nucleus when compared to controls. Specifically,
there was an increase in perinuclear mitochondria
(controls 100 ± 6.2, sAD 112 ± 11.1, PSEN1 136.9 ±
12.9; p b 0.05 and p b 0.005 respectively; Fig. 1C).
Both sAD and PSEN1 fibroblasts had a higher
proportion of long mitochondria (% long mitochondria
of total mitochondria controls 46 ± 14, sAD 65 ± 11,
PSEN1 73 ± 11; Fig. 1D) indicating a more fused
mitochondrial network. Conversely, the % of the cell
area occupied by small mitochondria was decreased.
The form factor of the overall mitochondria network
was altered, which upon further investigation was due
to the “small” mitochondrial components having
higher form factor than in controls (data normalized
to controls: controls 100% ± 3%, sAD 106% ± 2.5%,
PSEN 111% ± 3%). We also found a correlation
between the functional abnormalities and morpholog-
ical changes; mitochondrial membrane potential and
% long mitochondria showed a negative correlation
(p = 0.0002, R2 = 0.7; Fig. 1E).
Next we investigated mitochondrial respiration in
both sAD fibroblasts and PSEN1 mutant fibroblasts
using the “mito stress test” on the Seahorse Analyser.
This assay was undertaken on a limited number of
sAD fibroblast lines (n = 5) andPSEN1 fibroblast lines
(n = 2) due to poor growth of the other fibroblast lines.
The Seahorse trace shows a reduction in oxygen
consumption in each sAD fibroblast line measured
compared to controls, whereas there is an increase in
each PSEN1 patient fibroblast line (Fig. 2A–E).
Specifically, we found a significant reduction in
spare capacity in sAD fibroblasts of 34% when
compared to controls (p b 0.05); this varied between
a 15% reduction and a 35% reduction in the sAD
fibroblasts; the variability is shown in Fig. 2A–E. The
PSEN1 patient fibroblasts showed significant in-
creases in mitochondrial respiration (increased by
52%, p b 0.01), ATP-coupled respiration (increased
by 48%, p b 0.01) and spare capacity (increased
58%, p b 0.05; Fig. 2F). The reductions in spare mito-
chondrial capacity show correlation with mitochondrial
membrane potential deficits (p = 0.003, R2 = 0.65;
Fig. 2G); this is with the exclusion of the PSEN1
sample as this has reduced mitochondrial membrane
potential, yet increased spare capacity. The Seahorse
Analyser also simultaneously measures extracellular
acidification rate (ECAR); we, however, did not find
any significant alterations in basal or stimulated ECAR
rates in the sAD or PSEN1 patient fibroblasts (data not
shown).
UDCA improves mitochondrial phenotype in sAD
and PSEN1 fibroblasts
After identifying mitochondrial abnormalities in both
sAD and PSEN1 patient fibroblasts, we next investi-
gated if these mitochondrial parameters could be
improved by treatment with UDCA. Treatment with
100 nMUDCA increasedmitochondrial respiration and
ATP-coupled respiration in both sAD and PSEN1
patient fibroblasts by 32% and 51%, respectively
(Fig. 2F, *p b 0.05). There was no effect of UDCA on
maximal capacity or uncoupled respiration. Treatment
with UDCA also increased MMP (controls 2.1 ± 1.6,
sAD 11.2 ± 2, PSEN1 24.7 ± 1.5; p b 0.05; Fig. 3A).
This increase varied across AD fibroblast lines with an
increase in mitochondrial membrane potential of
between 12% and 28% (Fig. 3A). Furthermore,
although the total mitochondrial morphology parame-
ters were not significantly altered by UDCA treatment,
the % long mitochondria was significantly reduced
(controls +5 ± 2.8, sAD −24.5 ± 10.7, PSEN1 −40.2 ±
2.1; p b 0.05; Fig. 3B).
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Mitochondrial morphology proteins are changed
in AD patient fibroblasts; UDCA modulates
mitochondrial fission proteins
We investigated both mRNA and protein expression
of the mitochondrial fission and fusion modulators
Drp1, mitofusin 1 (Mfn1), Mfn2 and optic atrophy 1
(Opa1). We found no significant alterations in
mRNA expression of any mitochondrial fission/fusion
modulators in the sAD or PSEN1 patient fibroblasts
(Supplementary Fig. 1A–D). Furthermore,weassessed
the protein expression of the same mitochondrial
modulators and found a reduction in the total cellular
protein expression of Drp1 in both sAD and PSEN1
Fig. 2. OCRs.PanelsA–FshowanOCR trace for controls (black circle solid line,n = 6), sporadic [gray squares andsolid line,
sAD1 (A), sAD2 (B), sAD3 (C), sAD4 (D), sAD5 (E)] and PSEN1 [gray squares and solid line, PSEN1 (F)] cell lines in the
untreated condition. Sporadic patient fibroblasts have a reduction inOCR compared to controls at baseline andwhenmeasuring
maximal capacity, but PSEN1 cell lines have an increase at both points. Panels A–F show the reduction seen in spare capacity in
sporadic cell lines (*p b 0.05) and the increase seen in PSEN1 cell lines compared to controls (*p b 0.05). Fibroblasts after
treatment with 100 nMUDCA for 24 h show increasedmitochondrial respiration in both sAD (*p b 0.05) and PSEN1 (*p b 0.05)
fibroblasts (A–F). Each measurement was repeated on three separate passages of each cell line. (G) Mitochondrial membrane
potential shows correlation with spare respiratory capacity (p = 0.003,R2 = 0.65). The circles represent controls; squares, sAD;
and triangles, PSEN1. The PSEN1 fibroblasts were excluded from linear regression calculations.
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cohorts (controls 100 ± 12.2, sAD 37.8 ± 19.7, PSEN1
64.5 ± 22.5; p b 0.05; Fig. 4A). Example Western blots
from each fibroblast line are given in Fig. 4A(ii) and
Supplementary Fig. 1E. Total levels of Drp1 expression
were increased after treatment with UDCA in sAD [sAD
dimethyl sulfoxide (DMSO) treated 37.4 ± 11.5, sAD
UDCA treated 74.5 ±31.6; p b 0.05; Fig. 4A]. Levels of
the other mitochondrial modulators were unaltered at
protein level (Supplementary Fig. 1G). We next
assessed the subcellular distribution of Drp1 using
immunofluorescence staining. Drp1 is normally cyto-
solic and is recruited to the outer mitochondrial
membrane at points of fission by receptors on the
outer mitochondrial membrane such as mitochondrial
fission 1 protein (Fis1), MFF, Mid49 and Mid51. Drp1
then acts in a pincer-like fashion to surround the outer
mitochondrial membrane and pinch it together forming
two daughter mitochondria. The quantification of our
Drp1 staining showed that the AD patient fibroblasts
(both sAD and PSEN1) have less Drp1 specifically at
their mitochondria (controls 100 ± 11.13, sAD 32.77 ±
11.63, PSEN1 36.58 ± 9.35; p b 0.01; Fig. 4B). This
indicates that Drp1 is not being recruited successfully to
mitochondria. UDCA treatment increased theamount of
Drp1 localized at the mitochondria membrane in both
the sAD and PSEN1 patient fibroblasts (sAD DMSO
treated 43.66 ± 4.62, sAD UDCA treated 74.88 ± 6.67,
PSEN1 DMSO treated 33.86 ± 1.83, PSEN1 UDCA
treated 74.5 ± 8.2; p b 0.05; Fig. 4B).
Drp1 knockdown abolishes UDCA protective
effect in sAD and PSEN1 fibroblasts
To elucidate if the protective effect of UDCA was
mediated by Drp1, we undertook knockdown experi-
ments of Drp1 in control andADpatient fibroblasts.We
achieved a knockdown of Drp1 protein levels at 48 h
post-transfection of 40% compared to scramble siRNA
negative control for each fibroblast line (Fig. 5A). This
meant that the Drp1 level in the AD fibroblasts after
knockdown was 25% of control levels as Drp1 levels
are already lower in AD fibroblasts. Drp1 knockdown in
control fibroblasts did not result in reductions in
mitochondrial membrane potential; however, mito-
chondrial morphology was altered. Mitochondria
were more elongated [form factor (normalized to
controls as %) controls 100 ± 5, controls with Drp1
k/d 113 ± 3.3; p b 0.05, Fig. 5B] with an increased
amount of the cell area occupied by longmitochondria
(controls scramble 46 ± 2.3, controls Drp1 k/d 59 ±
3.4; p b 0.05). Similar changes were observed in AD
fibroblasts after Drp1 knockdown with no effect on
mitochondrial membrane potential but increased
further % of cell area occupied by long mitochondria
(sAD scramble 65 ± 3.4, sAD Drp1 k/d 74.4 ± 4.5;
PSEN1 scramble 72.7 ± 5.3, PSEN1 Drp1 k/d 81.2 ±
5.2). However, the increase in mitochondrial mem-
brane potential observed in AD fibroblasts after UDCA
treatment was not seen in the Drp1 knockdown
condition (Fig. 5D). Similarly, the “corrections” in
mitochondrial morphology seen after UDCA treatment
were not seen in the Drp1 knockdown condition
(Fig. 5B). We investigated Drp1 cellular localization
under conditions of Drp1 knockdown. We observed,
as expected, less Drp1 colocalizing with mitochondria
in all cells withDrp1 knockdown; UDCA treatmentwas
not able to change this (Fig. 5C).
Discussion
Here we show that detectable alterations in both
mitochondrial function and morphology are found in
Fig. 3. Recovery with UDCA treatment. (A) Fibroblasts are treated for 24 h with 100 nM UDCA. UDCA treatment, however,
increases mitochondrial membrane potential. The increase from the untreated state for controls, sporadics and familial cell lines
varies between 0 and 5% for controls, 12% and 28% for sAD and 19% and 21% for PSEN1 (*p b 0.05). (B) The increase in
mitochondrial membrane potential when fibroblasts are treated with 100 nM of UDCA. The relative increase from the untreated
state for controls, sporadics and familial cell lines is 0%, 11% and 25%, respectively (*p b 0.05). Each measurement was
repeated on three separate passages of each cell line.
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peripheral fibroblasts from two separate cohorts of
sAD patients and a group of PSEN1 familial AD
patients. Mitochondrial membrane potential is re-
duced in all seven sAD fibroblast lines tested and the
three PSEN1 fibroblast lines. It is noteworthy that we
did not stress the cells at any point in order to reveal
these mitochondrial abnormalities; they were identi-
fiable under “normal glucose” culture conditions.
Mitochondrial membrane potential was more variable
in theADpatient fibroblasts than the control fibroblasts.
We postulate that this is a feature of investigating sAD
patients; the underlying cause of sporadic disease and
disease stage at which each biopsy was collected is
not known for every patient. These factors are likely to
increase variability in these mitochondrial measures
more than in controls without a neurodegenerative
condition.
Abnormalities in the mitochondria of patients have
been shown before [4,6,26], and it has also been
shown that the amyloid protein itself can affect the
function of mitochondria [27]. This is one of the first
studies to directly compare sAD and familial AD
Fig. 4. Drp1 protein expression. (A) Total Drp1 protein expression levels are reduced in both sAD (light gray bars) and
PSEN1 (dark gray bars) fibroblasts (**p b 0.01). After treatment with 100 nM UDCA, total Drp1 levels are increased in the
sAD fibroblasts (*p b 0.05). A(ii) Representative western blot showing control untreated (lane 1), control DMSO treated
(lane 2), control 100 nMUDCA (lane 3), control 10 μMUDCA (lane 4), sAD untreated (lane 5), sAD DMSO treated (lane 6),
sAD 100 nM UDCA treated (lane 7) and sAD 10 μM UDCA treated (lane 8) for Drp1 and loading control actin. (B) Drp1
cellular localization is altered in sAD and PSEN1 fibroblasts. Significantly less Drp1 colocalizes with the mitochondrial
marker (TOMM20) in the sAD (light gray bars) and PSEN1 (dark gray bars) fibroblasts (***p b 0.005); however, after
treatment with 100 nMUDCA for 24 h, the amount of Drp1 which colocalizes with the mitochondria is increased (*p b 0.05;
**p b 0.01). B(ii) Representative images of control fibroblasts vehicle treated (a) and treated with UDCA (b) and sAD
fibroblasts vehicle treated (c) and treated with UDCA (d) and PSEN1 vehicle treated (e) and treated with UDCA (f). Blue
staining is Hoechst for the nucleus, green staining is Drp1 and red staining is TOMM20 for the mitochondria. Each
measurement was repeated on three separate passages of each cell line; for immunocytochemistry measurements, at
least 150 cells were imaged per fibroblast line per experiment.
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patient derived fibroblasts at the same time.
Although both sAD and PSEN1 patient fibroblasts
have mitochondrial abnormalities, the level of defect
varies between sAD and PSEN1 fibroblasts. Partic-
ularly striking is the increase in mitochondrial
respiration in the PSEN1 mutant fibroblasts, where-
as the spare respiratory capacity was reduced in the
sAD fibroblast cohort. These biochemical data are
difficult to interpret; the opposite effects found when
investigating respiration and mitochondrial membrane
potential in PSEN1 patient fibroblasts may suggest
that the mitochondria are uncoupled. Some evidence
for this can be gained from theSeahorses traces as the
coupling efficiency is reduced in PSEN1 fibroblasts
even if respiration is increased. Alternatively, as
fibroblasts do not rely heavily on oxidative phosphor-
ylation in order to maintain energy state, particularly in
glucose media, this could suggest that PSEN1
mutants rely heavily on alternative energy pathways.
This would best be investigated in additional cell types
which rely to varying degrees on glycolysis versus
oxidative phosphorylation. The recent study by Sonn-
tag et al. [7] investigated mitochondrial respiration in a
cohort of late-onset AD patient fibroblasts and found
the mitochondrial respiration rates to be higher than
controls, similar to the PSEN1 fibroblast lines we
tested here. The apparent discrepancy between our
sAD and the study by Sonntag et al. could in part be
Fig. 5. Drp1 knockdown data. (A) Drp1 protein expression knockdown of 48% from scramble siRNA levels (*p b 0.05).
(B) Mitochondrial form factor is increased in sAD and PSEN1 fibroblasts in the scramble siRNA condition, which is reduced
again after UDCA treatment. Drp1 knockdown increases form factor in all fibroblasts. UDCA does not have an effect on
mitochondrial form factor in the Drp1 knockdown condition. (C) Image showing Drp1 staining in green, mitochondria in red and
nuclei in blue. A representative image is shown for each condition. Control scramble siRNA (i), control scramble siRNA+UDCA
(ii), control Drp1 siRNA (iii), control Drp1 siRNA +UDCA (iv); sAD scramble siRNA (v), sAD scramble siRNA +UDCA (vi), sAD
Drp1 siRNA (vii), sAD Drp1 siRNA +UDCA (viii); PSEN1 scramble siRNA (ix), PSEN1 scramble siRNA +UDCA (x), PSEN1
Drp1 siRNA (xi), PSEN1 Drp1 siRNA +UDCA (xii). (D) Mitochondrial membrane potential is reduced in sAD and PSEN1
fibroblasts in the scramble siRNA condition, which is increased with UDCA treatment. In the Drp1 siRNA condition, there is no
further decrease in mitochondrial membrane potential; however, UDCA treatment does not increase mitochondrial membrane
potential.
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due to differences in the age of the patients, the cell
culture conditions and passage of the cells at
measurement. The sAD patients included in this
study, particularly those from the Sheffield cohort,
were young due to the patients being recruited at the
Sheffield young-onset clinic, whereas those sAD
patients biopsied in the study by Sonntag et al. were
late-onset sAD patients. The age of the donors is also
likely to explain the differences seen between our sAD
cohort and that of Sonntag et al. with regard to cellular
ATP levels. The global reductions inMMPwe describe
here largely concur with the previously published
literature from AD patient fibroblasts (both familial and
sporadic) [4,6,26,28,29]. The literature is clear that
mitochondrial abnormalities are present and detect-
able in peripheral fibroblasts from AD patients.
The reasons for these abnormalities, however, are
still being investigated. We show alterations in the
protein expression and subcellular localization of Drp1.
Drp1 levels have been implicated as a cause of
mitochondrial abnormalities in sAD before, with reduc-
tions in Drp1 protein levels found in sAD fibroblasts
[13,29], which could be rescued by Drp1 over
expression [13]. PSEN1 fibroblasts appear to be
less affected than sAD fibroblasts. PSEN1 has been
shown to increase activity at the mitochondrial
associated membrane [30]; therefore, it may be having
a direct role in controlling mitochondrial morphology,
which is not present in sAD patients. The sAD cohort
used in our study may have mitochondrial impairment
as a more central pathological mechanism, and
therefore, abnormalities are more pronounced when
measured in particular in young onset sAD patients, as
these patients mitochondria seem to have aged more
rapidly than that of late-onset sAD patients and
controls. The recycling of dysfunctional mitochondria
is a process that Drp1 is also intimately involved
with and has been shown by others to be defective in
at least PSEN1 patient fibroblasts [29]. We did
not investigate mitophagy in this report; however, this
is a potential mechanism that could be investigated
further.
Previous work by Manczak and colleagues [31] has
shown an interaction between Drp1 and the amyloid
protein in the brain of an APP mouse model. In this
paper, partial reduction of Drp1 protein expression
reduces the production of amyloid-beta and improves
the mitochondrial dysfunction seen in an APP mouse
model of AD. This same group has also shown that a
reduction in Drp1 leads to a reduction in phosphory-
lated tau in themouse brain [32]. It is plausible that the
mis-localization of Drp1 that we have shown in our
study is exacerbated in the brain by interaction with
amyloid-beta as described in the above mouse
models of AD. Our work further highlights the need
to investigate Drp1 manipulation in other cell types
such as neurons.
UDCA has been used in the treatment of primary
biliary sclerosis for over 30 years. It has a limited
side effect profile and is a relatively safe drug [33].
Furthermore, UDCA has been tested in several cell
and animal models of AD and showed a putative
protective effect [34–37]. Here we show that UDCA
restores mitochondrial membrane potential in both
sAD and PSEN1 mutant fibroblasts; it, however, has
no significant effect on mitochondrial morphology.
However, we did find significant changes in the
amount of Drp1 localizing to the mitochondria
which increased in both sAD and PSEN1 fibroblasts,
close to control levels. To verify if UDCA is acting
via a pathway involving Drp1 in AD fibroblasts, we
examined the protective effect of UDCA under a
Drp1 knockdown condition; we found that knock-
down of Drp1 levels abolished the protective effect
of UDCA on mitochondrial membrane potential and
mitochondrial morphology. This knockdown was tran-
sient as it was employed in the primary fibroblasts as a
further validation sAD fibroblasts could be immortal-
ized with subsequent Drp1 knockdown; further valida-
tion using single siRNA's would also strengthen this
mechanistic link. As Drp1 knockdown in control cells
did not result in significant reduction of mitochondrial
membrane potential, it is plausible that UDCA modu-
lation of Drp1 is part of a wider pathway altered by
UDCA treatment without UDCA interacting directly
with Drp1 itself. Drp1 is known to undergo a complex
array of post-translational modifications including
nitrosylation, ubiquitinylation, sumoylation and phos-
phorylation. In particular several phosphorylation sites
have been identified; some promote mitochondrial
fragmentation (via cyclin B) and others promote
elongation via phosphorylation by protein kinase A.
This phosphorylation site has been shown to inhibit
disassembly of the Drp1 catalytic cycle, therefore
accumulating large Drp1 oligomers on the outer
mitochondrial membrane [38]. In this study, we did
not investigate any of the post-translational modifica-
tions of Drp1 or any of the other known pathways that
can affect Drp1 localization or phosphorylation state
(including AMPK, protein kinase A and ERK); there-
fore, this should be investigated further to fully
elucidate the mechanism of action of UDCA in AD.
Furthermore, Drp1 has been implicated in the ER–
mitochondrial contact sites (or mitochondrial associat-
ed membranes) where PSEN1 is known to increase
activity in AD. The investigation of ER–mitochondrial
contact sites is beyond the scope of this study;
however, it would be important to investigate this
pathway to assess the target by which UDCA is
acting. Identifying the exact subcellular target by
which UDCA is acting in AD is important for future
therapeutic applications of UDCA and other potential
neuroprotective compounds. Altering mitochondrial
fission modulators has not been proposed before as a
mechanism for UDCA and therefore warrants further
investigation in other patient derivedmodels and other
animal models that have previously showed protec-
tion of UDCA.
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In conclusion, our study has shown for the first time
that reduced mitochondrial membrane potential in AD
patient fibroblasts can be corrected with the treatment
of UDCA via a pathway, which includes Drp1. Our
study has identified a potential novel pathway by which
UDCA has mitochondrial protective effects and further
builds the case for the use of UDCA as a potential
neuroprotective therapy for neurodegenerative
disease.
Methods and Materials
Patient details
Fibroblasts from patients with sporadic and PSEN1
mutations were obtained from the NIGMS Human
Genetic Cell Repository at the Coriell Institute for
Medical Research: GM08243, GM07375, and
GM07376 (all male, mean age 67.6 years, SD 6.65)
and ND41001, ND34733, and ND34730 (2 male,
1 female, mean age 48.33 years, SD 11.06). These
fibroblasts were compared with control fibroblasts
(mean age 59.3 years, SD 6.35) from the same
repository [GM07924, GM02189, GM23967 (all male)].
A second cohort of sporadic patient fibroblasts
(2 male, 2 female, mean age 59.25 years, SD 5.37)
and two aged matched controls (3 male, 1 female,
mean age 60.66 years, SD 2.08) were also sampled
from a local population of patients involved in the
MODEL-AD research study (Research and Ethics
Committee number: 16/YH/0155). The McKhannn et
al. [39] criteria were used to diagnose AD, and
participants took part in the European wide Virtual
Physiological Human: Dementia Research Enabled by
IT (VPH-DARE@IT).
Cell culture
Primary fibroblast cells were cultured continuously
using methods performed essentially as described
by Mortiboys et al [24]. Cells were grown in EMEM
(4500 g/L glucose), supplemented with 10% FBS,
100 UI/ml penicillin, 100 μg/ml streptomycin, 50 μg/ml
uridine and 1 mM sodium pyruvate, 0.1 mM amino
acids, and 0.1 × MEM vitamins. For mitochondrial
membrane potential,morphology cellswereplated at a
density of 2500 cells per well in a black 96-well plate.
UDCA (Sigma-Aldrich Ltd) was added to culturemedia
(10 mM and 100 nM) 24 h prior to assay. DMSO was
used as vehicle control.
Mitochondrial morphology
Mitochondrial membrane potential and mitochondri-
al morphological parameters were measured using
tetramethlyrhodamine staining of live fibroblasts.
Briefly, 24 h after drug treatment, cells were incubated
with 80 nM tetramethlyrhodamine and 10 μMHoescht
in phenol red-free media for 1 h. Cells were washed
and imaged using the InCell Analyzer 2000 high-
content imager (GE Healthcare). Raw images were
processed and parameters obtained using a custom
protocol in InCell Developer software (GE Healthcare)
allowing for segmentation of mitochondria, nuclei and
cell boundaries.
Western blots
Cell pellets from patient and control fibroblasts were
lysed using RIPA buffer and Protein Inhibitor Cocktail
on ice, and protein levels were measured using a
Bradford Assay. Twenty micrograms of protein was
run on a 12% SDS-PAGE gel and transferred to a
polyvinylidene fluoride membrane. Membranes were
incubated overnight at 4 °C, with mouse anti-Drp1
(Abcam; 1:1000), mouse anti-OPA1 (BD Biosciences;
1:1000), mouse anti-Mfn1 (Abcam; 1:1000) or rabbit
anti-Mfn2 (St Johns Laboratory; 1:500). Membranes
were also probed for β actin as a loading control
(St Johns Laboratory; 1:1000). Membranes were then
incubated with goat anti-mouse HRP (Abcam;
1:10,000) or goat anti-rabbit HRP (Dako; 1:5000),
as appropriate. Membranes were imaged using the
G box chemi system using GeneSnap software
(Syngene). Densitometry was analyzed using Gene-
Tools software (Syngene).
RNA extraction and qPCR
Fibroblasts were treated with UDCA 10uM and
100 nM 24 h prior to harvesting. Approximately
750,000 cells where harvested for each RNA extrac-
tion. RNAextractionwas performed using anRNAeasy
Plus Mini Kit (Qiagen) and by following Quick-start
supplied protocol. RNA was converted into compli-
mentary DNA using the QuantiTect Reverse Tran-
scription Kit (Qiagen), standard Quick-Start supplied
protocols were followed. qPCR was performed on a
Stratgene PCR machine. Samples were loaded at
12.5 ng/μl per well. Sybr Green was used as the de-
tection dye for the chain reaction, and a standard two-
step program with 40 amplification cycles was used
during the PCR. Primer sequences were as follows:
Drp1: forward ATTATGCCAGCCAGTCCACAA, re-
verse CGCTGTTCCCGAGCAGATA; Mfn1: forward
CACTCCAGCAACGCCAGATA, reverse CGGACGC
CAATCCTGTTACT; Mfn2: forward GTCTGACCTGG
ACCACCAAG, reverse TGCAGTTGGAGCCAGTGT
AG; and Opa1: forward AGCCAGTCCAAGCAGG
ATTC, reverse TGCTTTCAGAGCTGTTCCCT.
Metabolic flux assay
Oxygen consumption rate (OCR) and ECAR were
measured using a 24-well Agilent seahorse XF
analyzer machine (Agilent). Human fibroblasts where
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plated at a density of 60,000 cells per well. Cells where
treated with UDCA 100 nM for 24 h prior to measure-
ment. Three measurements of OCR and ECAR were
taken in each state: basal state, after the addition
of oligomycin (0.5 μM), FCCP (0.5 μM) and rotenone
(1 μM). A cell count was then done on a fixed assay
plate using a Hoechst dye (1 μM). Data presented in
this paper are normalized to cell number.
Immunocytochemistry
Cells were fixed in 4% paraformaldehyde and then
permeabilized with 0.1% Triton. After blocking, cells
were incubatedwith anti-mouseDrp1 (BDBiosciences;
1:1000) and anti-rabbit TOM20 (Santa Cruz Biotech-
nology; 1:1000). Cells were then incubated with Alexa
Fluor anti-rabbit 568 and Alexa Fluor anti-mouse 488
and 1 μMHoechst. Cells were imaged using theOpera
Phenix high-content imager (PerkinElmer). z Stacks
were collected and analyzed using Harmony software
(PerkinElmer).
Drp 1 knockdown experiments
Cells were plated as above for the mitochondrial
membrane potential and morphology assays. Cells
were treated with either 100 nM Drp1 siRNA SMART
pool Accell probes (Horizon Discovery) or 100 nM
scramble siRNA-negative Accell probes in Accell
delivery media. After 24 h, 100 nM UDCA was
added to the treatment conditions, and 24 h later, the
assays carried out.
Statistical tests
Data are presented as normalized mean ± SD
unless otherwise stated. For UDCA-treated parame-
ters (ATP and MMP), data are presented as percent-
age increase from untreated basal levels. Data were
analyzed using GraphPad Prism Software (V7.02):
one-way ANOVA with Tukey's multiple comparisons
posttest or, for UDCA-treated data, two-way ANOVA
with Tukey's multiple comparisons posttest. In addi-
tion, t test was used to compare each individual AD
fibroblast line to the control group for MMP.
Supplementary data to this article can be found
online at https://doi.org/10.1016/j.jmb.2018.08.019.
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